Invokana Increases Risk of Bone Fractures, FDA Warns
The Food and Drug Administration (FDA) issued a safety announcement in September warning patients and health care providers of an increased risk of bone fractures in patients taking the type 2 diabetes drugs Invokana and Invokamet (canagliflozin). The FDA deemed the new safety announcement necessary because bone fractures have been … [Read more...]
FDA Warns about Bone Fracture Risks with Invokana
The Food and Drug Administration (FDA) has updated the warning label of the type 2 diabetes drug canagliflozin (Invokana, Invokamet) to warn about the increased risk of bone fractures and reduced bone mineral density for those taking canagliflozin. This warning comes soon after an FDA warning in May in which the agency said Invokana … [Read more...]
FDA Warns of Increased Bone Fracture Risk for Diabetes Patients Taking Invokana and Invokamet
Last week, the Food and Drug Administration (FDA) issued a safety communication providing information on bone fracture risk and decreased bone density in patients taking the diabetes drugs Invokana and Invokamet (canagliflozin). The FDA has strengthened the warning for the type 2 diabetes medication canagliflozin (Invokana, … [Read more...]
